reason report
expect
bottom line market close pti releas full-
year earn result pti transit new year
encouragingli long await data three program
amplifi corrector potenti cystic fibrosi
cf link endors two influenti cf pt advocaci
group could expedit compani trial allow pti get
market faster link breakthrough therapi orphan drug
design link link although op lead
tripl combo candid top-lin result announc
pti remain confid plan advanc program
compani believ could yield remark efficaci link pti plan
initi tripl combo trial
preliminari result expect deliv addit catalyst
could increment derisk program pti end year
cash report year-end ep loss per
share light breakthrough design could eas
pti program market assum approv rais
probabl success po three program
rais pt reiter op
doubl tripl combo therapi data expect recal
pti deliv long await data encourag includ
result award breakthrough orphan drug design
link link link pti plan initi tripl
preliminari result expect
result orkambi pt initi data doubl
program pti announc today start
new program cf patient op symdeko
initi studi provid initi data earli could help
pti gain part market add-on therapi push
proprietari therapi parallel
pti recent award breakthrough pt advocaci group
endors help expedit clinic trial although
breakthrough therapi synergist effect
breakthrough design pt advocaci group endors
us eu could help move program faster compani
may alreadi benefit pt advocaci group endors
consid cf pt background orkambi enrol
ahead schedul
continu next page
rate termin growth rate
compani inform leerink partner llc research
revenu mm ep present
pleas refer page import disclosur price chart analyst certif
pti end year cash report year-
end ep loss per share increas po
program news pti breakthrough design
adjust opex calibr market assumpt
publish leerink colleagu cover op
rais pt
rate pti share outperform proteostasi pti emerg biotechnolog compani
whose lead candid design work amplifi work addit
vrtx orkambi corrector/potenti combin increas function cftr
cell membran pti gener intrigu preclin data view suggest
may abl significantli augment clinic effect orkambi approv us
eu use cystic fibrosi cf patient delta mutat despit orkambi
strong commerci success medacorp kol view orkambi current effect rel
modest least compar kalydeco smaller cf subpopul gate
mutat kol believ market opportun could larg orkambi
abl boost benefit significantli accordingli penetr estim match
leerink orkambi penetr estim delta homozygot sinc
drug would use combin base project benefit amplifi
also assum modest penetr harder-to-treat heterozyg delta popul
look key catalyst next month elucid role could
play cf treatment landscap beyond compani develop turbo
corrector combin plu proprietari corrector potenti
combin gener addit data futur valuat driven
probability-weight assess potenti
current estim probabl success launch base
assum price per year us per year row estim gross
peak revenu opportun po world-wide
deriv price target correspond market capit month
model assum probabl success po
approv commerci cystic fibrosi cf patient mutat
us row compani drt diseas relev translat platform seek identifi
novel drug candid optim screen process assign valu
earli preclin asset overal valuat pti expect advanc
 cf pursu collabor opportun
one astella price target base dcf analysi use
discount rate termin growth rate
risk includ disappoint clinic data regulatori setback potenti dilut financ
commerci shortfal sinc pti product candid enter clinic trial
aforement setback could impact stock significantli commerci front
lead candid develop add-on potentiator/corrector combin
orkambi thu success could hing orkambi sale well competitor effort
augment activ orkambi moreov novel technolog ameliorate/enhance/repair
ctfr cf patient exampl could also neg impact pti market potenti
pti except ep share
revenu milestones/collabor
net incom tax
net incom tax
net loss attribut common stockhold
chang cash
chang fair valu deriv liabil
chang fair valu pref stock warrant liabil
issuanc common share
issuanc conv prefer stock net cost
issuanc convert promissori note
exercis stock option
discount rate/cost equiti
initi cf patient
result three cohort orkambi patient day dose
initi clinicc studi cf subject symdeko
initi data cf patient
preliminari result cf patient
initi data cf subject symdeko
pt nation cf registri
pt homozyg
penetr orkambi
penetr tez/iva
penetr triplet combo
penetr
penetr combo
pt treat
pt heterozyg
penetr orkambi
penetr tez/iva
penetr triplet combo
penetr
penetr combo
pt treat
price us
pt nation cf registri
pt homozyg
penetr orkambi
penetr tez/iva
penetr triplet combo
penetr
penetr
pt treat
pt heterozyg
penetr orkambi
penetr tez/iva
penetr triplet combo
penetr
penetr
pt treat
cf
total pt treat
total pt treat
price row
probabl success us
probabl success row
